Investors are closely examining the performance of two small-cap finance companies, WhiteHorse Finance (NASDAQ: WHF) and Advanced Medical Isotope (OTCMKTS: RDGL). A recent analysis compares the two firms based on several key factors including valuation, earnings, profitability, analyst recommendations, and risk.
Volatility and Risk Assessment
The volatility of these companies presents important insights for potential investors. Advanced Medical Isotope has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500. In contrast, WhiteHorse Finance has a beta of 0.56, reflecting a share price that is 44% less volatile than the benchmark index. These figures suggest that both companies are relatively stable investments compared to broader market fluctuations.
Ownership stakes also tell a compelling story. Institutional investors hold 13.2% of WhiteHorse Finance shares, while insiders own 18.5% of Advanced Medical Isotope. Notably, only 2.5% of WhiteHorse Finance shares are held by company insiders. The higher percentage of insider ownership at Advanced Medical Isotope may signal confidence from those closely associated with the company.
Profitability and Analyst Recommendations
Profitability metrics further illuminate the comparative strengths of these two firms. Recent data from MarketBeat.com indicates that WhiteHorse Finance exhibits stronger earnings and revenue than Advanced Medical Isotope. The consensus price target for WhiteHorse Finance stands at $7.75, suggesting a potential upside of 11.51%. Analysts appear to favor WhiteHorse Finance, as reflected in its higher consensus rating and projected growth.
In summary, WhiteHorse Finance surpasses Advanced Medical Isotope in 9 out of 11 evaluated factors, indicating a stronger overall performance and investor outlook.
Company Profiles
Advanced Medical Isotope, now known as Vivos Inc., is a radiation oncology medical device company based in Richland, Washington. The company specializes in developing brachytherapy devices for the treatment of non-resectable tumors. Its flagship products include the yttrium-90 based RadioGel, used for brachytherapy radiation treatment, and IsoPet, designed for treating solid tumors in animals. Vivos Inc. was incorporated in 1994 and rebranded in December 2017.
On the other hand, WhiteHorse Finance functions as a business development company, focusing on originating senior secured loans to lower middle-market industries. The firm invests primarily in sectors such as broadline retail, healthcare services, and data processing. Typical investments range from $5 million to $25 million in companies with an enterprise value between $50 million and $350 million.
As the market continues to evolve, the comparative analysis of WhiteHorse Finance and Advanced Medical Isotope offers valuable insights for investors seeking to navigate the complexities of small-cap finance.
